NKM Immune Cell Therapy


Succeeded in Research & Development (Characteristics of Oda NKM Immune Cell Therapy)

  • The Culture medium is a crucial factor for the immune cell culture: Succeeded in the development of a culture medium for human NKM cells
     Model Number: OKM series
    The culture medium is said to be “a decisive factor in inducing the high-quality features of the cells, and is a heart part of the cell culture.”
    At Oda Bio-Immuno Laboratory, we continued researching and developing on the medium, and we newly developed NKM cell culture media with the highest quality (OKM series).
    By this success, Oda Clinic offers NKM Cell Therapy that utilizes the cells with the highest quality.
    These cultivating media are the original products of Oda Bio-Immuno Laboratory, and at present, they are exclusively used only in Oda Clinic.
    Our NK cells are different from those used in other clinics.
  • NKM Cell Therapy
    We are offering NKM Cell Therapy, which is a further evolution form of NK Cell Therapy, where T and B cells are mixed (M) into the culture during the course of NK cell-based proliferation and let those cells attack cancer cells strongly.
    In the case of NKM Cell Therapy, the number of NK cells in a single dose is an astounding number of about 1.5 to 3 billion cells (including T, B, and dendritic cells etc).
  • Intensive Care Method
    In addition to the above-mentioned basic method, NK Cell Therapy has an “Intensive Care Method” option, depending on the patient’s condition such as cancer.
    This is an intensive method, which the amounts of NK cell administered during one course of the therapy will be introduced ahead of time in a short time period. This treatment option will be considered on an individual basis, and we determine the therapeutic strategy based on the patient’s medical condition.

Case Report

A Case of a 73 years old Male

  • Chief Complaint
    Visit us to have a consultation with Oda Clinic.
  • Current Medical History

    Found a swelling in the right armpit in July 2002.

    At the time of first doctor visit on August 21, 2002, the diameter of the tumor was 8 cm. Diagnosed as malignant lymphoma (follicular) at a nearby hospital.

    Started chemotherapy from September 2002. After three months of chemotherapy, no improvement was observed but developed intense side effects such as palpitations and breath shortness etc.

    Visited our clinic in December 2002.

  • Examination Finding

    Superficial lymph nodes: irregular large and small lymph nodes were palpable in the right side armpit (several nodes of the size of 10×10 cm3, 6×6 cm3, 5×5 cm3, and 2×2 cm3).

    Conjunctiva: Jaundice (-), Anemia (+)

    Chest: No abnormality observed

    Abdomen: No abnormality observed

Implementation of the Adoptive Immunotherapy on the Patient
Administration Number Date of Administration Number of the Cell Administered Side Effects
1 20-Jan-03 29x108 None
2 27-Jan-03 26x108 None
3 3-Feb-03 33x108 None
4 10-Feb-03 30x108 None
5 24-Feb-03 30x108 None
6 10-Mar-03 28x108 None

NKM Immune Cell Therapy